<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03339596</url>
  </required_header>
  <id_info>
    <org_study_id>H-16038506</org_study_id>
    <secondary_id>RHP-2017-023</secondary_id>
    <secondary_id>2016-002326-36</secondary_id>
    <nct_id>NCT03339596</nct_id>
  </id_info>
  <brief_title>Effects of Erythropoietin for Cognitive Side-effects of ECT</brief_title>
  <acronym>EPO-T</acronym>
  <official_title>Erythropoietin as an add-on Treatment for Cognitive Side-effects of Electroconvulsive Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martin Balslev Jørgensen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Augustinus Foundation, Denmark.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mental Health Services in the Capital Region, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mental Health Services in the Capital Region, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      EPO-T aims to investigate (i) whether short-term add-on treatment with erythropoietin (EPO)&#xD;
      can reduce cognitive side-effects of ECT and (ii) whether such effects are long-lasting.&#xD;
      Further, structural and functional magnetic resonance imaging (MRI) will be used to explore&#xD;
      the neural underpinnings of such beneficial effects of EPO. Finally, the trial examines&#xD;
      whether potential protective effects of EPO on cognition are accompanied by changes in&#xD;
      markers of oxidative stress, inflammation, and neuroplasticity.&#xD;
&#xD;
      It is hypothesized that EPO treatment will (i) counteract ECT-induced cognitive decline,&#xD;
      accompanied by (ii) increased sub-regional hippocampal volume, (iii) greater memory-related&#xD;
      hippocampal activation and reinforcement of dorsolateral prefrontal activity during memory&#xD;
      encoding and working memory, and (iv) changes in peripheral markers of inflammation,&#xD;
      oxidative stress and neuroplasticity. Furthermore, we hypothesize that add-on EPO-treatment&#xD;
      will produce greater, more sustained mood improvement than ECT treatment alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial will include patients with a diagnosis of major depression (MDD) unipolar disorder&#xD;
      (UD) or bipolar disorder (BD) with a current moderate to severe depressive episode symptoms&#xD;
      (a score of &gt;17 on the Hamilton Depression Rating Scale 17-items (HRDS-17) scheduled for ECT&#xD;
      treatment. Patients will be recruited from Psychiatric Centres in The Mental Health Services&#xD;
      in the Capital Region of Denmark and will undergo an eligibility assessment prior to&#xD;
      randomization to 4 intravenous infusions of either recombinant human EPO (40.000 IU/ml;&#xD;
      Epoetin alpha; Eprex, Janssen-Cilag) or placebo (1 ml NaCl) diluted with 100 ml saline (0.9%&#xD;
      NaCl).&#xD;
&#xD;
      Cognitive functions, mood symptoms, and blood- and urine markers of inflammation, oxidative&#xD;
      stress, and neuroplasticity will be assessed 3 times during the trial. First time at&#xD;
      baseline, second time 3 days after ECT session 8 (patients skip one ECT session day after 8&#xD;
      ECTs to minimise the confounding effects of acute side-effects of ECT due to anaesthesia&#xD;
      etc.), and the third time at a 3 month follow-up after ECT completion. In addition, the&#xD;
      neuronal substrates for potential effects of EPO on cognition are investigated with&#xD;
      structural and functional MRI after 8 ECT sessions (after 3 weekly EPO or saline infusions).&#xD;
&#xD;
      Block randomization and power calculations have been conducted by the independent Pharma&#xD;
      Consulting Group AB (www.pharmaconsultinggroup.com). Treatment groups are stratified for age&#xD;
      (&gt;40 or &lt;40) and gender.&#xD;
&#xD;
      The difference in cognitive change between EPO and saline-treated groups from baseline to&#xD;
      post-treatment in our previous trial was 0.5 SD. Based on these findings, the sample size of&#xD;
      N=52 (n=26 per group) in the current trial will reach a &gt;0.8 power to detect a clinically&#xD;
      relevant difference in the primary outcome measure (the cognitive composite score) between&#xD;
      the 2 groups at an alpha level of 5% (two-sided test). The study is also powered to&#xD;
      investigate differences in functional magnetic resonance imaging (fMRI) blood-oxygen&#xD;
      dependent level (BOLD) response in key neural networks based on previous fMRI studies from&#xD;
      our group in which sample sizes of 30 age and gender matched participants (n=15 per group)&#xD;
      had the power of &gt;0.8 to show drug-related effects on task-related neural response at an&#xD;
      alpha level of p&lt;0.05. In the current trial, inclusion of 52 participants (n=26 per treatment&#xD;
      group) therefore ensures sufficient statistical power to detect EPO-related effects on neural&#xD;
      activity.&#xD;
&#xD;
      Behavioural, mood, and biomarker data will be analysed using Mixed Models Design and&#xD;
      Intention to Treat (ITT) approaches. Resting state and task-related fMRI data will be&#xD;
      pre-processed and analyzed using FMRIB Expert Analysis Tool (FEAT) and the 'randomize'&#xD;
      algorithm integrated in FSL, FMRIB Software Library (www.fmrib.ox.ac.uk/fsl).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 26, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive composite score</measure>
    <time_frame>Change from baseline to week 4 (i.e., after the last EPO injection and 8th ECT session)</time_frame>
    <description>A cognitive composite score based on an average of the Rey Auditory Verbal Learning Test (RAVLT), The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Coding, Verbal Fluency with the letter &quot;D&quot;, Wechsler Adult Intelligence Scale (WAIS)-III Letter-Number Sequencing, Trail Making Test Part B, and Rapid Visual Information Processing (RVP) from the Cambridge Neuropsychological Test Automated Battery (CANTAB Cognition Ltd.).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Autobiographical Memory Interview-Short Form (AMI-SF)</measure>
    <time_frame>Baseline, week 4 (i.e., after the last EPO injection and 8th ECT session), and 3 months after ECT treatment completion</time_frame>
    <description>Neuropsychological test assessing retrograde autobiographical memory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rey Auditory Verbal Learning Test (RAVLT)</measure>
    <time_frame>Baseline, week 4 (i.e., after the last EPO injection and 8th ECT session), and 3 months after ECT treatment completion</time_frame>
    <description>Neuropsychological test assessing verbal learning and memory</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Rey Auditory Verbal Learning Test (RAVLT)</measure>
    <time_frame>Baseline, week 4 (i.e., after the last EPO injection and 8th ECT session), and 3 months after ECT treatment completion</time_frame>
    <description>Neuropsychological test assessing verbal learning and memory</description>
  </other_outcome>
  <other_outcome>
    <measure>The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Coding</measure>
    <time_frame>Baseline, week 4 (i.e., after the last EPO injection and 8th ECT session), and 3 months after ECT treatment completion</time_frame>
    <description>Neuropsychological test assessing attention</description>
  </other_outcome>
  <other_outcome>
    <measure>Verbal Fluency with the letter &quot;D&quot;</measure>
    <time_frame>Baseline, week 4 (i.e., after the last EPO injection and 8th ECT session), and 3 months after ECT treatment completion</time_frame>
    <description>Neuropsychological test assessing executive functions</description>
  </other_outcome>
  <other_outcome>
    <measure>Wechsler Adult Intelligence Scale (WAIS)-III Letter-Number Sequencing</measure>
    <time_frame>Baseline, week 4 (i.e., after the last EPO injection and 8th ECT session), and 3 months after ECT treatment completion</time_frame>
    <description>Neuropsychological test assessing executive functions</description>
  </other_outcome>
  <other_outcome>
    <measure>Trail Making Test Part B</measure>
    <time_frame>Baseline, week 4 (i.e., after the last EPO injection and 8th ECT session), and 3 months after ECT treatment completion</time_frame>
    <description>Neuropsychological test assessing executive functions</description>
  </other_outcome>
  <other_outcome>
    <measure>Rapid Visual Information Processing (RVP) from the Cambridge Neuropsychological Test Automated Battery (CANTAB Cognition Ltd.)</measure>
    <time_frame>Baseline, week 4 (i.e., after the last EPO injection and 8th ECT session), and 3 months after ECT treatment completion</time_frame>
    <description>Neuropsychological test assessing sustained attention</description>
  </other_outcome>
  <other_outcome>
    <measure>Hamilton Depression Rating Scale 17-items Version</measure>
    <time_frame>Baseline, week 4 (i.e., after the last EPO injection and 8th ECT session), and 3 months after ECT treatment completion</time_frame>
    <description>Clinician-based interview assessing depression severity</description>
  </other_outcome>
  <other_outcome>
    <measure>Beck Depression Inventory 21-items</measure>
    <time_frame>Baseline, week 4 (i.e., after the last EPO injection and 8th ECT session), and 3 months after ECT treatment completion</time_frame>
    <description>Questionnaire assessing subjectively-rated depression severity</description>
  </other_outcome>
  <other_outcome>
    <measure>Cognitive Complaints in Bipolar Disorder Rating Assessment</measure>
    <time_frame>Baseline, week 4 (i.e., after the last EPO injection and 8th ECT session), and 3 months after ECT treatment completion</time_frame>
    <description>Questionnaire assessing subjectively-rated cognitive complaints</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>ECT</condition>
  <condition>Cognitive Impairment</condition>
  <condition>Unipolar Depression</condition>
  <condition>Bipolar Depression</condition>
  <arm_group>
    <arm_group_label>Erythropoietin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 intravenous infusions of recombinant human erythropoietin (EPO)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 intravenous infusions of saline (1 ml NaCl)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin</intervention_name>
    <description>40.000 IU/ml Erythropoietin (Epoetin alpha; Eprex) diluted with 100 ml saline (0.9% NaCl) is administered 4 times as intravenous infusions over 15 minutes.</description>
    <arm_group_label>Erythropoietin</arm_group_label>
    <other_name>Eprex</other_name>
    <other_name>EPO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>1 ml NaCl is administered 4 times as intravenous infusions over 15 minutes</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ICD-10 diagnosis of major depressive disorder/unipolar disorder or bipolar disorder&#xD;
             (confirmed using the Mini International Neuropsychiatric Interview; M.I.N.I.) with&#xD;
             current moderate to severe depressive episode symptoms&#xD;
&#xD;
          -  Hamilton Depression Rating Scale 17-items score ≥17&#xD;
&#xD;
          -  Fluent Danish skills&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment under involuntary measures&#xD;
&#xD;
          -  Other neuropsychiatric conditions&#xD;
&#xD;
          -  Alcohol or substance misuse disorder&#xD;
&#xD;
          -  Recent suicide attempts&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Kidney disease&#xD;
&#xD;
          -  Renal failure&#xD;
&#xD;
          -  Untreated/insufficiently treated arterial hypertension&#xD;
&#xD;
          -  Heart diseases (previously diagnosed or abnormal ECG findings during screening)&#xD;
&#xD;
          -  Previous or current epilepsy in patient or first degree family&#xD;
&#xD;
          -  Malignancies or thromboses&#xD;
&#xD;
          -  Known allergy or antibodies against erythropoietin&#xD;
&#xD;
          -  Initial hematocrit &gt; 50% (males) or &gt; 48% (females)&#xD;
&#xD;
          -  Initial thrombocyte numbers over normal (&gt;400 billions/L)&#xD;
&#xD;
          -  Initial reticulocyte numbers &lt;1‰&#xD;
&#xD;
          -  Contraindications against prophylactic thrombosis treatment&#xD;
&#xD;
          -  Myeloproliferative disorder, polycythemia&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Use of contraceptive medication or other hormonal contraceptives&#xD;
&#xD;
          -  Sexually active women in the fertile age, who do not or do not want to use double&#xD;
             barrier anticontraceptive methods&#xD;
&#xD;
          -  Previous or current history of thromboembolic events or thromboses in patient or first&#xD;
             degree family (increased risk of thromboembolic events)&#xD;
&#xD;
          -  Overweight (BMI&gt;30) or body weight &lt;45 or &gt;95 kg.&#xD;
&#xD;
          -  Previous electroconvulsive therapy (ECT) treatment within last 3 months&#xD;
&#xD;
          -  Reluctance or inability to comply with the protocol requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin B. Jørgensen, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Psychiatric Centre Copenhagen, Rigshospitalet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kamilla W. Miskowiak, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Psychiatric Centre Copenhagen, Rigshospitalet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin B. Jørgensen, Prof.</last_name>
    <phone>38647082</phone>
    <phone_ext>38647082</phone_ext>
    <email>martin.balslev.joergensen@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kamilla W. Miskowiak, Prof.</last_name>
    <phone>38647087</phone>
    <phone_ext>38647087</phone_ext>
    <email>kamilla.woznica.miskowiak@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mental Health Services, Capital Region of Denmark, Copenhagen University Hospital, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <state>Copenhagen O</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin B Jørgensen, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>October 24, 2017</study_first_submitted>
  <study_first_submitted_qc>November 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2017</study_first_posted>
  <last_update_submitted>November 9, 2017</last_update_submitted>
  <last_update_submitted_qc>November 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mental Health Services in the Capital Region, Denmark</investigator_affiliation>
    <investigator_full_name>Martin Balslev Jørgensen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>electroconvulsive therapy</keyword>
  <keyword>depression</keyword>
  <keyword>cognition</keyword>
  <keyword>cognitive side-effects</keyword>
  <keyword>erythropoietin</keyword>
  <keyword>functional magnetic resonance imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

